论文部分内容阅读
雌激素受体(ER)是乳腺癌发生、发展最为重要的分子生物学标志物,其状态在乳腺癌的预后、临床治疗策略、内分泌治疗疗效预测等方面具有非常重要的临床价值。当前ER状态测定方法以肿瘤标本免疫组化法为代表,但均为有创、离体测定,存在取材等诸多因素影响和限制,临床内分泌治疗疗效的预测也远不够完美。FES是一种雌激素类似物,能够特异地与雌激素受体结合,FES-PET能够有效表达肿瘤ER的生物活性,采用标准摄取值客观定性、定量分析。FES-PET与病理测定结果密切相关,能有效评估乳腺癌原发灶及转移灶ER状态,并预测内分泌治疗疗效,有望成为临床无创测定肿瘤ER状态的有效方法。
Estrogen receptor (ER) is the most important molecular biomarker of breast cancer. Its status is of great clinical value in the prognosis of breast cancer, clinical treatment strategies and the prediction of the therapeutic effect of endocrine therapy. Current ER status measurement methods are represented by immunohistochemistry of tumor samples, but all are invasive and ex vivo determination, there are many factors such as the impact and limitations, the prediction of clinical efficacy of endocrine therapy is far from perfect. FES is an estrogen analog that binds estrogen receptor specifically. FES-PET can effectively express the biological activity of tumor ER, and objectively and quantitatively analyzed by standard uptake. FES-PET is closely related to the pathological results, which can effectively evaluate the ER status of primary and metastatic breast cancer and predict the efficacy of endocrine therapy. It is expected to become an effective method for clinical non-invasive determination of ER status.